The prevalence of allergic diseases, mainly allergic rhinitis and urticaria, is increasing steadily worldwide and has a significant effect on patients’ financial health costs and quality of life.
Histamine is the main mediator involved in the pathophysiology of these diseases, which is why Evidence Based Medicine (EBM) clearly indicates that antihistamines should be the first therapeutic option for allergic rhinitis and urticaria.
The development of a new and modern antihistamine, which will become available this year in almost all of Europe, increases our therapeutic options to the benefit of allergic patients.
During this Symposium, three internationally recognised experts will present the most recent information concerning results in patients, the EBM guidelines and the most up-to-date information and understanding of research into antihistamines.
